^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD73 overexpression

    i
    Other names: CD73, 5'-Nucleotidase Ecto, Ecto-5'-Nucleotidase, 5'-Nucleotidase, 5'-NT, NT5, NTE, 5'-Nucleotidase, Ecto (CD73), Purine 5-Prime-Nucleotidase, 5' Nucleotidase (CD73), CD73 Antigen, E5NT
    Entrez ID:
    4907
    Related biomarkers:
    Expression
    Others
    1year
    Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1H,3H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase. (PubMed, J Med Chem)
    Immunoassays suggested that 35j remarkably increased the infiltration of positive immune cells, thereby reinvigorating antitumor immunity. These results demonstrate that 35j is a potent CD73 inhibitor worthy of further development.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • PSAP (Prostatic Acid Phosphatase)
    |
    CD73 overexpression • CD73 expression
    almost2years
    CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway. (PubMed, Proc Natl Acad Sci U S A)
    These results demonstrate that the catalytic activity of CD73 contributes to the pathogenic growth of FN-RMS through the activation of the purinergic signaling pathway. Therefore, targeting CD73 and the purinergic signaling pathway represents a potential therapeutic approach for FN-RMS patients.
    Journal
    |
    CD73 (5'-Nucleotidase Ecto) • NT5E (5'-Nucleotidase Ecto)
    |
    CD73 overexpression • CD73 expression
    2years
    One Tube 23 Color Full Spectral Flow Cytometry Panel in Detecting Minimal Residual Disease in Pediatric B-Cell Acute Lymphoblastic Leukemia (ASH 2023)
    Results The limit of blank (LOB), limit of detection (LOD), and lower limit of quantitation (LLOQ) were firstly determined, the results showed reproducible sensitivity up to 0.001% (1-in-105) after acquisition of 4.8 million cells for 23-color panel...Conclusion Based on these evidences, SMFC-based one-tube 23-color MRD panel for B-ALL was convenient and maneuverable with higher sensitivity and specificity compared to conventional 8-color FC-MRD panel. It would be a promising method to improve the risk stratification.
    Clinical • IO biomarker • Minimal residual disease
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD73 (5'-Nucleotidase Ecto) • CD123 (Interleukin 3 Receptor Subunit Alpha) • CD22 (CD22 Molecule) • CD44 (CD44 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • CD200 (CD200 Molecule) • CD24 (CD24 Molecule) • MME (Membrane Metalloendopeptidase) • CD58 (CD58 Molecule) • CEACAM6 (CEA Cell Adhesion Molecule 6) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • NRP1 (Neuropilin 1) • ANPEP (Alanyl Aminopeptidase, Membrane) • CD81 (CD81 Molecule) • CD86 (CD86 Molecule)
    |
    CD73 overexpression • CD44 expression • TNFRSF8 overexpression
    2years
    Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells. (PubMed, Life Sci)
    In contrast, CD73 overexpression dramatically reduced the in vivo anticancer activity of Bortezomib in immunocompetent mice, with tumor growth inhibition rates from 52.18 % for LLC/vector down to 8.75 % for LLC/NT5E homografts. These findings give new insights into the anticancer mechanisms of proteasome inhibitors.
    Journal
    |
    NT5E (5'-Nucleotidase Ecto) • FGF2 (Fibroblast Growth Factor 2)
    |
    CD73 overexpression • CD73 expression • NT5E overexpression
    |
    bortezomib
    2years
    Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR. (PubMed, J Immunother Cancer)
    BsAb CD73xEGFR outperforms oleclumab as it inhibits the CD73/ADO immune checkpoint in an EGFR-directed manner and concurrently counteracts several oncogenic activities of EGFR and CD73. Therefore, bsAb CD73xEGFR may be of significant clinical potential for various forms of difficult-to-treat solid cancer types.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • CD8 (cluster of differentiation 8) • NT5E (5'-Nucleotidase Ecto)
    |
    CD73 overexpression • CD73 expression • NT5E overexpression
    |
    oleclumab (MEDI9447)
    2years
    Overexpression of CD73 is associated with recurrence and poor prognosis of gingivobuccal oral cancer as revealed by transcriptome and deep immune profiling of paired tumor and margin tissues. (PubMed, Cancer Med)
    High infiltration of anti-tumor immune cells in both tumors and margins results in good prognosis, while in patients with minimal infiltration in tumors in spite of high infiltration in margins results in poor prognosis. Targeted CD73 immune-checkpoint inhibition may improve clinical outcome.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto) • TLR4 (Toll Like Receptor 4) • ITGA6 (Integrin, alpha 6) • RBP1 (Retinol Binding Protein 1) • THRA (Thyroid Hormone Receptor Alpha) • BMPR1B (Bone Morphogenetic Protein Receptor Type 1B)
    |
    CD73 overexpression • CD73 expression • NT5E overexpression
    2years
    CD73 mitigates hepatic damage in alcoholic steatohepatitis by regulating PI3K/AKT-mediated hepatocyte pyroptosis. (PubMed, Biochem Pharmacol)
    Our results show a novel function of CD73 regulates hepatocytes pyroptosis and highlights the therapeutic opportunity for reducing the disease process in ALD.
    Journal
    |
    NT5E (5'-Nucleotidase Ecto) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    CD73 overexpression • CD73 expression • NT5E overexpression
    over2years
    CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma. (PubMed, Cancer Manag Res)
    Monocytes from MM exhibited weakened anti-tumor effects, and CD73 was involved in forming an immunosuppressive microenvironment. Inhibiting CD73 partly restored the anti-tumor activity of monocytes, a potential strategy for the treatment of MM.
    Journal
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • NT5E (5'-Nucleotidase Ecto) • SDC1 (Syndecan 1) • IL4 (Interleukin 4)
    |
    CD73 overexpression • IFNG expression • CD73 expression • IL10 elevation
    over2years
    Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy. (PubMed, Sci Adv)
    Depletion of adenosine in the TME by the repurposed drug PEGylated adenosine deaminase (PEG-ADA) increases CD8 T cell activity and enhances response to ICI therapy. Use of PEG-ADA can therefore be a therapeutic option to overcome resistance to ICIs in cancer patients.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • STAT3 (Signal Transducer And Activator Of Transcription 3) • NT5E (5'-Nucleotidase Ecto)
    |
    CD73 overexpression • CD73 expression • NT5E overexpression
    over2years
    Therapeutic targeting of HIF-1 alpha induced CD73 expression in experimental esophageal adenocarcinoma (AACR 2023)
    Nanoparticle albumin-bound paclitaxel (NPT) was used as chemotherapeutic agent, whereas acriflavine was used as hypoxia-targeting agent... These results support the potential of acriflavine as HIF-1 alpha and CD73 targeting and its combination with chemotherapy NPT as an effective option for EAC therapy.
    PARP Biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • NT5E (5'-Nucleotidase Ecto) • CASP3 (Caspase 3)
    |
    CD73 overexpression • CD73 expression • HIF1A expression
    |
    albumin-bound paclitaxel
    almost3years
    CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. (PubMed, Adv Sci (Weinh))
    Diclofenac also enhances the therapeutic efficacy of gemcitabine in the spontaneous KPC (LSL-Kras , LSL-Trp53 , and Pdx-1-Cre) pancreatic cancer model. Therefore, diclofenac may be an effective anti-CD73 therapy, when used alone or in combination with gemcitabine-based chemotherapy regimen, for metastatic PDAC.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PDX1 (Pancreatic And Duodenal Homeobox 1) • TRIM21 (Tripartite Motif Containing 21)
    |
    CD73 overexpression • CD73 expression
    |
    gemcitabine
    almost3years
    CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report. (PubMed, J Thorac Oncol)
    Oleclumab plus osimertinib showed evidence of moderate activity with acceptable tolerability in previously treated patients with advanced EGFR-mutated NSCLC.
    Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR T790M • CD73 overexpression • EGFR negative • EGFR T790M negative • CD73 expression
    |
    Tagrisso (osimertinib) • oleclumab (MEDI9447)